



Cite this: *Chem. Commun.*, 2017, 53, 6712

Received 18th April 2017,  
Accepted 31st May 2017

DOI: 10.1039/c7cc02988h

[rsc.li/chemcomm](http://rsc.li/chemcomm)

**A homogeneous carbene-based palladium catalyst was conjugated to a cell-penetrating peptide, allowing intracellular delivery of catalytically active Pd complexes that demonstrated bioorthogonal activation of a profluorophore within prostate cancer cells.**

In recent years, bioorthogonal organometallic reactions have been successfully applied in chemical biology.<sup>1–8</sup> In particular, Pd-mediated chemical transformations have been used to modify or synthesise molecules through cleavage of protecting groups or cross-coupling reactions.<sup>5,9</sup> The first use of Pd chemistry in mammalian cells was reported by Bradley,<sup>10</sup> who trapped Pd nanoparticles within an inert polymer microsphere for intracellular delivery. This “active” transition metal catalyst was used to mediate C–C bond formation *via* Suzuki–Miyaura cross-coupling and allyl carbamate cleavage reactions inside living cells, including the intracellular activation of a prodrug of the antineoplastic agent amsacrine. This approach was also used to convert propargyl derivatives of 5-fluorouracil and gemcitabine to their active forms, as well as catalyse Suzuki–Miyaura cross-couplings of drugs in the presence of an extracellular heterogeneous Pd catalyst.<sup>11–13</sup> Pd-mediated transformations have since been used to selectively activate biomolecules in cells. Chen developed the chemical activation of proteins based on the decaging of propargylcarbamate caged lysine with simple Pd salts, while Pd(NO<sub>3</sub>)<sub>2</sub>, Pd(dba)<sub>2</sub>, and allyl<sub>2</sub>PdCl<sub>2</sub> have also been used to mediate Sonogashira cross-coupling reactions inside bacteria,<sup>14</sup> or to activate a protein of interest inside cells.<sup>14–17</sup> However, under optimised conditions, 50 equivalents of these Pd complexes were required for the completion of the cross-coupling reactions.<sup>16</sup> The major drawbacks of all the above methods are the lack of cell selectivity of the catalyst and the use of stoichiometric, or even excess (up to 500 eq.), Pd complex and the cellular

toxicity when used in non-complexed/encapsulated form.<sup>5,18</sup> Targeted localisation of a Pd catalyst, by means of cell selective delivery of a homogeneous catalyst, would represent a major advance in the field.

Herein, we have extended the scope of Pd catalysed chemistry in living systems by developing a method to deliver and track an active organometallic complex inside mammalian cells. These water-soluble and traceable catalysts were based on a Pd(n)-carbene complex coupled to a fluorescently labelled homing peptide for targeted cell delivery. The biocompatible homogeneous Pd catalyst was based on a previously reported carbene Pd ligand coupled to a peptide.<sup>19,20</sup> N-Heterocyclic carbenes (NHC) are strong  $\sigma$ -electron donating molecules (enhancing the rate of oxidative addition), coordinate tightly to Pd centres (disfavouring aggregation), and can have bulky substituents (increasing the rate of reductive elimination).<sup>21,22</sup> Peptides were chosen to deliver the Pd complex inside cells as they are biocompatible, easy to prepare by solid-phase peptide synthesis (SPPS), versatile, readily labelled and functionalised, with known cell delivery abilities.<sup>23</sup>

The polycationic (tri-lysine) catalyst **1** represented a simple cell penetrating peptide (CPP) which was able to cross the cell membrane,<sup>23</sup> and could be readily labelled to allow tracking of the catalyst inside cells.


Here, either 5(6)-carboxyfluorescein (FAM,  $\lambda_{\text{ex/em}} = 492/517$  nm) or sulfonated Cy5 ( $\lambda_{\text{ex/em}} = 630/654$  nm) were attached to the peptides to give the fluorescent Pd-catalysts **2** and **3**, respectively (Scheme 1). Peptides **1**, **2** and **3** were synthesised on a Rink amide linker functionalised aminomethyl polystyrene resin using standard Fmoc/Bu SPPS with Oxyma/DIC as the coupling combination (Scheme 1 and ESI<sup>†</sup>). Coupling of the fluorophores in **2** and **3** was achieved by introducing a bis-*N*-[1-(4,4-dimethyl-2,6-dioxocyclo hexylidene) ethyl] (Dde) protected Lys as the first amino acid (Fmoc-Lys(Dde)-OH). Prior to Fmoc removal of the terminal Lys residue, the Dde group was orthogonally removed with hydroxylamine<sup>24</sup> and the liberated amine coupled to the activated dye. The imidazole ligand **4** was coupled to the amino terminus of the peptides using TBTU as

EaStCHEM, School of Chemistry, University of Edinburgh, David Brewster Road, EH9 3FJ Edinburgh, UK. E-mail: [Mark.Bradley@ed.ac.uk](mailto:Mark.Bradley@ed.ac.uk)

<sup>†</sup> Electronic supplementary information (ESI) available: Experimental section, Proc-rhodamine decaging and biological studies. See DOI: [10.1039/c7cc02988h](https://doi.org/10.1039/c7cc02988h)

<sup>‡</sup> These authors contributed equally.






**Scheme 1** Synthetic route to the Pd-peptide catalysts on a Rink functionalised polystyrene resin.

an activating agent. The imidazole salt was treated with the base BEMP to form the carbene, which was subsequently trapped by the addition of dichloro(1,5-cyclooctadiene) palladium(II) (PdCl<sub>2</sub>COD) as the source of Pd.<sup>19</sup> The catalysts were cleaved from the resin by treatment with TFA (5% water, addition of conventional scavenging agents destroyed the Pd complex) and

purified by preparative HPLC. To evaluate the catalytic activity in a biological setting, non-fluorescent bis-propargyloxycarbonyl (Proc) rhodamine 110 (5) was treated with Pd catalyst 1 in phosphate buffered saline (PBS) and PC-3 (prostate adenocarcinoma) cell lysate (see ESI†). Upon Pd catalysed cleavage of the protecting groups with 0.1 eq. of 1 for 24 h, fluorescent 6 was generated giving a 200-fold increase in fluorescence. The reaction in cell lysate resulted in a more modest 9-fold relative increase in fluorescence with 0.1 eq. of the catalyst, but demonstrated that the Pd-peptide hybrid was catalytically competent even in the presence of a complex mixture of biomolecules.

The cellular uptake of the carboxyfluorescein labelled Pd-peptide 2 was investigated with the total quantity of the internalised Pd determined by inductively coupled plasma optical emission spectrometry (ICP-OES) analysis of PC-3 cells (Fig. 1B), giving a total Pd content of 20 ng per million cells (when incubated with 30  $\mu$ M of 2 for 2 h), showing a higher metal uptake compared to cells treated with 10  $\mu$ M of Pd(OAc)<sub>2</sub> (higher concentration of Pd(OAc)<sub>2</sub> showed cytotoxicity). Catalyst 2 showed no cytotoxicity even at 200  $\mu$ M (see ESI†). The cellular uptake and intracellular location of the Pd catalyst 2 was investigated by flow cytometry and confocal microscopy (Fig. 1C and D). PC-3 cells showed a shift of the whole cell population



**Fig. 1** Cellular uptake of Pd-peptide 2. (A) Structure of the carboxyfluorescein labelled Pd-peptide 2. (B) Intracellular Pd content (ng Pd per million cells) of PC-3 cells incubated with 10  $\mu$ M Pd(OAc)<sub>2</sub> or 2 (3  $\mu$ M and 30  $\mu$ M) for 2 h (higher concentrations of Pd(OAc)<sub>2</sub> were toxic). Cells were harvested, lysed and the cell content was subjected to ICP-OES measurements. (C) Flow cytometry histograms showing the uptake of 2 (30  $\mu$ M) in PC-3 cells after 2 h (in black) and untreated control cells (in grey). (D) PC-3 cells were incubated with 2 (30  $\mu$ M) for 2 h, fixed with 4% paraformaldehyde, stained with DAPI (nuclei stain) and imaged by confocal microscopy. Panels show (i) Pd catalyst 2 (green,  $\lambda_{ex} = 488$  nm) located in the cytoplasm and nucleus, (ii) cell nucleus (blue,  $\lambda_{ex} = 405$  nm), and (iii) merged image (light blue indicates co-localisation). Scale bar 20  $\mu$ m.




Fig. 2 Pd catalysed decaging of Proc-rhodamine **5** in PC-3 cells. (A) Catalysed fluorescence “switch-on” of the caged fluorophore **5** with the Pd–peptide complex **3**. Cells were incubated with Pd–peptide **3** (30  $\mu$ M) for 2 h, followed by incubation with **5** (50  $\mu$ M) for 18 h. (B) Confocal microscopy images of PC-3 cells fixed with 4% paraformaldehyde and stained with DAPI (nuclei stain). Panels show: (i) cell nucleus (blue,  $\lambda_{\text{ex}} = 405$  nm) and Pd–peptide **3** (magenta,  $\lambda_{\text{ex}} = 633$  nm), and (iii) merged image. Scale bar 20  $\mu$ m. (C) Flow cytometry cytograms showing: (i) untreated control cells, (ii) cells treated with Proc-rhodamine **5**, and (iii) cells treated with **5** and **3**.

towards higher fluorescence intensity after 2 h incubation with catalyst **2** (30  $\mu$ M), with the fluorescence localised within the cytoplasm and, unexpectedly, in the nucleus (cationic peptides generally localise in the cytoplasm and in vesicles<sup>25,26</sup>).

The catalytic activity of the Pd–peptide catalysts in cell-based assays *via* Proc-rhodamine **5** activation was investigated with the Cy5 labelled Pd–peptide **3**. PC-3 cells were incubated with **3** (30  $\mu$ M) for 2 h, washed to remove any extracellular catalyst, and subsequently incubated with **5** (50  $\mu$ M) for 18 h (Fig. 2A). Fluorescence microscopy verified the presence of the Pd-catalyst **3** as well as synthesised **6** within the cytoplasm of PC-3 cells (Fig. 2B). Analysis by flow cytometry showed a shift of the whole cell population towards higher fluorescence intensity in the Cy5 channel indicating the uptake of the catalyst, while a shift to higher FITC intensity indicated the formation of **6** (Fig. 2C).

In conclusion, we have demonstrated the ability to combine a catalytically active Pd complex with a cell-delivery peptide scaffold, which was able to catalyse a depropargylation reaction in a biologically relevant setting. The non-cytotoxic Pd catalyst was successfully used in the fluorescent labelling of mammalian cells, showing significant catalytic activity in an intracellular environment. Future applications will thus include the activation of prodrugs *via* these Pd catalysts. This new type of catalytic system gives the basis for a wide range of biocompatible catalysts, where their facile modification allows the incorporation of a

variety of different targeting peptides that could selectively enter different cells or specific tissues.

## Notes and references

1. C. Streu and E. Meggers, *Angew. Chem., Int. Ed.*, 2006, **45**, 5645–5648.
2. J. Li and P. R. Chen, *ChemBioChem*, 2012, **13**, 1728–1731.
3. G. Y. Tonga, Y. Jeong, B. Duncan, T. Mizuhara, R. Mout, R. Das, S. T. Kim, Y.-C. Yeh, B. Yan, S. Hou and V. M. Rotello, *Nat. Chem.*, 2015, **7**, 597–603.
4. J. Li and P. R. Chen, *Nat. Chem. Biol.*, 2016, **12**, 129–137.
5. M. Yang, J. Li and P. R. Chen, *Chem. Soc. Rev.*, 2014, **43**, 6511–6526.
6. M. Tomás-Gamasa, M. Martínez-Calvo, J. R. Couceiro and J. L. Mascareñas, *Nat. Commun.*, 2016, **7**, 12538.
7. J. Clavadetscher, S. Hoffmann, A. Lilienkampf, L. Mackay, R. M. Yusop, S. A. Rider, J. J. Mullins and M. Bradley, *Angew. Chem., Int. Ed.*, 2016, **55**, 15662–15666.
8. P. K. Sasmal, C. N. Streu and E. Meggers, *Chem. Commun.*, 2013, **49**, 1581–1587.
9. S. V. Chankeshwara, E. Indrido and M. Bradley, *Curr. Opin. Chem. Biol.*, 2014, **21C**, 128–135.
10. R. M. Yusop, A. Unciti-Broceta, E. M. V. Johansson, R. M. Sánchez-Martín and M. Bradley, *Nat. Chem.*, 2011, **3**, 239–243.
11. J. T. Weiss, J. C. Dawson, K. G. Macleod, W. Rybski, C. Fraser, C. Torres-Sánchez, E. E. Patton, M. Bradley, N. O. Carragher and A. Unciti-Broceta, *Nat. Commun.*, 2014, **5**, 3277.
12. J. T. Weiss, J. C. Dawson, C. Fraser, W. Rybski, C. Torres-Sánchez, M. Bradley, E. E. Patton, N. O. Carragher and A. Unciti-Broceta, *J. Med. Chem.*, 2014, **57**, 5395–5404.
13. E. Indrido, J. Clavadetscher, S. V. Chankeshwara, A. Lilienkampf and M. Bradley, *Chem. Commun.*, 2016, **52**, 14212–14214.
14. J. Li, S. Lin, J. Wang, S. Jia, M. Yang, Z. Hao, X. Zhang and P. R. Chen, *J. Am. Chem. Soc.*, 2013, **135**, 7330–7338.



15 J. Li, J. Yu, J. Zhao, J. Wang, S. Zheng, S. Lin, L. Chen, M. Yang, S. Jia, X. Zhang and P. R. Chen, *Nat. Chem.*, 2014, **6**, 352–361.

16 N. Li, R. K. V. Lim, S. Edwardraja and Q. Lin, *J. Am. Chem. Soc.*, 2011, **133**, 15316–15319.

17 C. D. Spicer and B. G. Davis, *Chem. Commun.*, 2013, **49**, 2747–2749.

18 C. P. Ramil and Q. Lin, *Chem. Commun.*, 2013, **49**, 11007–11022.

19 K. Worm-Leonhard and M. Meldal, *Eur. J. Org. Chem.*, 2008, **2008**, 5244–5253.

20 J. F. Jensen, K. Worm-Leonhard and M. Meldal, *Eur. J. Org. Chem.*, 2008, **2008**, 3785–3797.

21 W. A. Herrmann, *Angew. Chem., Int. Ed.*, 2002, **41**, 1290–1309.

22 G. Altenhoff, R. Goddard, C. W. Lehmann and F. Glorius, *Angew. Chem., Int. Ed.*, 2003, **42**, 3690–3693.

23 S. Deshayes, M. C. Morris, G. Divita and F. Heitz, *Cell. Mol. Life Sci.*, 2005, **62**, 1839–1849.

24 J. J. Díaz-Mochón, L. Bialy and M. Bradley, *Org. Lett.*, 2004, **6**, 1127–1129.

25 R. Fischer, K. Köhler, M. Fotin-Mleczek and R. Brock, *J. Biol. Chem.*, 2004, **279**, 12625–12635.

26 G. Drin, S. Cottin, E. Blanc, A. R. Rees and J. Temsamani, *J. Biol. Chem.*, 2003, **278**, 31192–31201.

